Implantica AG (publ) said it will publish its Q2 2026 interim report at 8:00 a.m. CEST on August 21 and host an English-language results presentation at 15:00 CEST the same day via webcast and teleconference. CEO Peter Forsell, CFO Andreas Öhrnberg and Chief Corporate Affairs Officer Nicole Pehrsson are scheduled to speak. The medtech company, listed on Nasdaq First North Premier Growth Market in Stockholm under IMP A SDB, said its lead product RefluxStop® is a CE-marked (approved for European market use) implant for gastroesophageal reflux disease (GERD) and highlighted a broader patent-protected implantable technology pipeline.